{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')","uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')","type":"itsystems.Pd.DataServices.DataModel.Business"},"BusinessResponsibilities":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/BusinessResponsibilities"}},"RelatedBusinesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/RelatedBusinesses"}},"BusinessRoles":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/BusinessRoles"}},"Publications":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Publications"}},"LegislativePeriods":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/LegislativePeriods"}},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Sessions"}},"Preconsultations":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Preconsultations"}},"Bills":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Bills"}},"Councils":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Councils"}},"BusinessTypes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/BusinessTypes"}},"Votes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Votes"}},"SubjectsBusiness":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/SubjectsBusiness"}},"BusinessStates":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/BusinessStates"}},"Council":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Council"}},"Transcripts":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20227663,Language='FR')/Transcripts"}},"ID":20227663,"Language":"FR","BusinessShortNumber":"22.7663","BusinessType":14,"BusinessTypeName":"Heure des questions. Question","BusinessTypeAbbreviation":"Qst.","Title":"Prix des m\u00e9dicaments : comment expliquer l'immense marge de profit des groupes pharmaceutiques ?","Description":null,"InitialSituation":null,"Proceedings":null,"DraftText":null,"SubmittedText":"<p>Une \u00e9tude publi\u00e9e par Public Eye estime les co\u00fbts de recherche et de d\u00e9veloppement et calcule, par exemple, la marge de profit pour 6 m\u00e9dicaments contre le cancer largement utilis\u00e9s\u00a0: de 40 \u00e0 90\u00a0%. Sur 1000 francs pay\u00e9s par l'assurance maladie obligatoire, le groupe pharmaceutique re\u00e7oit donc jusqu'\u00e0 900 francs de b\u00e9n\u00e9fice.</p><p>- Le Conseil f\u00e9d\u00e9ral partage-t-il l'avis selon lequel de telles marges de profit sont injustifi\u00e9es et excessives\u00a0?</p><p>- Comment explique-t-il cette situation aux payeurs de primes\u00a0?</p>","ReasonText":null,"DocumentationText":null,"MotionText":null,"FederalCouncilResponseText":null,"FederalCouncilProposal":null,"FederalCouncilProposalText":null,"FederalCouncilProposalDate":null,"SubmittedBy":"Porchet L\u00e9onore","BusinessStatus":229,"BusinessStatusText":"Liquid\u00e9","BusinessStatusDate":"\/Date(1663545600000)\/","ResponsibleDepartment":4,"ResponsibleDepartmentName":"D\u00e9partement de l'int\u00e9rieur","ResponsibleDepartmentAbbreviation":"DFI","IsLeadingDepartment":true,"Tags":"15|2841","Category":null,"Modified":"\/Date(1758206343333)\/","SubmissionDate":"\/Date(1663113600000)\/","SubmissionCouncil":1,"SubmissionCouncilName":"Conseil national","SubmissionCouncilAbbreviation":"CN","SubmissionSession":5116,"SubmissionLegislativePeriod":51,"FirstCouncil1":1,"FirstCouncil1Name":"Conseil national","FirstCouncil1Abbreviation":"CN","FirstCouncil2":null,"FirstCouncil2Name":null,"FirstCouncil2Abbreviation":null,"TagNames":"\u00c9conomie|Sant\u00e9"}}